Sabrina Paganoni, MD, PhD

@PaganoniMDPhD

ALS clinician scientist; physiatrist dedicated to ALS clinical trials and assistive technology;

Boston, MA
Vrijeme pridruživanja: ožujak 2014.

Tweetovi

Blokirali ste korisnika/cu @PaganoniMDPhD

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @PaganoniMDPhD

  1. Prikvačeni tweet
    2. sij

    Great way to start 2020! The Healey for ALS at Mass General, in partnership with TackleALS and , is leading the first Platform Trial for ALS- less placebo, more options, more drugs tested -> goal is to accelerate the path to ALS treatments

    Poništi
  2. proslijedio/la je Tweet
    prije 19 sati

    You can read here a summary of our "Innate Immune Hypothesis of Alzheimer's Disease" connecting infection and genetic risk factors as the causes of Alzheimer's disease

    Poništi
  3. proslijedio/la je Tweet

    There is not a red state version of ALS and a blue state version of ALS. There is only ALS. There is not a pro-ALS group and anti-ALS group, there is 1 movement to end ALS. We speak with different words but seek the same future. We fight for each other and will be the cure.

    Poništi
  4. proslijedio/la je Tweet

    Have you heard about the AAP's new Program? Matching is now open! Mentees, sign in now to select your top mentor - it's first come, first served so act fast. Not involved? Learn more and sign up!

    Poništi
  5. proslijedio/la je Tweet
    4. velj

    Hard work & dedication have helped Dr. Deborah Venesy become 's Vice President. She is an amazing example of the power of . Read more from Dr. Venesy and other inspirational female at . 👩‍⚕️

    Poništi
  6. proslijedio/la je Tweet

    2/ "It is through these collective efforts that we are creating a platform for scientific inquiry that can lead to breakthrough discoveries." -Dr. Hemali Phatnani. VIDEO PART 2

    Prikaži ovu nit
    Poništi
  7. proslijedio/la je Tweet

    1/ "To date, over 3,000 genomic and clinically annotated samples from patients have been sequenced and analyzed, and this dataset, one of the largest cohorts in the world, is available to all researchers." -Dr. Hemali Phatnani VIDEO PART 1

    Prikaži ovu nit
    Poništi
  8. proslijedio/la je Tweet

    Did you know it's National ? Read about neuromuscular disease patient Hattie McBride's journey here!

    Poništi
  9. proslijedio/la je Tweet
    3. velj

    Long-term safety and efficacy of eculizumab in generalized myasthenia gravis - read this 2019 Top Accessed article in Muscle and Nerve

    Poništi
  10. proslijedio/la je Tweet
    30. sij

    FDA Gives OK to HEALEY Platform Trial Testing Zilucoplan, CNM-Au8, and Verdiperstat. covers trial co-led by investigator Sabrina Paganoni, MD.

    Poništi
  11. proslijedio/la je Tweet
    28. sij

    Merit Cudkowicz, MD, MSc, Director of the Healey Center for ALS, discusses the impact of the “May Proceed” notice from the FDA for three drugs in first ALS platform trial via

    Poništi
  12. proslijedio/la je Tweet
    27. sij

    The FDA has approved to proceed with administering three proposed drug regimens in the HEALEY ALS Platform Trial. The is a part of this platform. For more information, check out:

    Poništi
  13. proslijedio/la je Tweet
    27. sij

    Is there an association between mild cognitive impairment, social engagement, and mobility? Dr. and her team share their findings

    Poništi
  14. proslijedio/la je Tweet
    23. sij

    When took our fight to Congress and showed us each that we have the power to change the world.

    Poništi
  15. proslijedio/la je Tweet
    22. sij

    Amazing news in today! Very excited for the platform trial and the hard work by and making this highly efficient trial possible!

    Poništi
  16. proslijedio/la je Tweet
    22. sij

    We are excited to announce the FDA’s clearance of the IND application for the HEALEY Platform Trial, led by the Sean M. Healey & AMG Center at . To learn more:

    Poništi
  17. proslijedio/la je Tweet

    's Healey Center and its collaborators are one step closer to accelerating therapies for people with . Read the full press release here.

    Poništi
  18. proslijedio/la je Tweet
    22. sij

    The Healey Center for ALS has received approval from the U.S. Food & Drug Administration (FDA) to proceed w/administering 3 proposed drug regimens in the HEALEY ALS Platform Trial – the first trial of its kind for ALS.

    Poništi
  19. proslijedio/la je Tweet
    17. sij

    What a week for the ALS community! 1 Congressional Gold Medal. 11 meetings with 29 congressional leaders. 100 House ALS Caucus members strong. 30+ media outlets talking about . 1 collective community out to change the world.

    Poništi
  20. proslijedio/la je Tweet
    17. sij

    Congratulations to our friend and volunteer leader, on her new role ! We're sure that will be in good, capable hands!

    Poništi
  21. proslijedio/la je Tweet
    16. sij

    Hot off the Press!! Congrats to Dr. Mónica Verduzco-Gutierrez (), an accomplished Physiatrist, recently named PM&R Chair Long School of Medicine!! 🎉 Look forward to working with you!

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·